Navigation Links
Vanda Pharmaceuticals Provides Update on Iloperidone
Date:9/11/2008

ROCKVILLE, Md., Sept. 11 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA), a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders, reported today that it met with the FDA on September 10, 2008 and discuss the iloperidone non-approvable action letter that the company received on July 25, 2008.

Vanda presented arguments to support its belief that iloperidone's benefit risk profile, as it was characterized in over 3,000 patients, suggests that iloperidone may be a useful agent for patients with schizophrenia.

Vanda has now agreed to provide a complete response to the FDA, in order to address the concerns raised by the FDA in their July 25, 2008 action letter. The timing or outcome of any FDA review is uncertain at this time.

ABOUT VANDA PHARMACEUTICALS INC.:

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. For more on Vanda Pharmaceuticals Inc., please visit http://www.vandapharma.com.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Various statements in this release are "forward-looking statements" under the securities laws. Words such as, but not limited to, "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," and "could," and similar expressions or words, identify forward- looking statements. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Vanda is at an early stage of development and may not ever have any products that generate significant revenue. Important factors that could cause actual results to differ materially from those reflected in the company's forward-looking statements include, among others: delays in the completion of Vanda's clinical trials; a failure of Vanda's product candidates to be demonstrably safe and effective; Vanda's failure to obtain regulatory approval for its products or to comply with ongoing regulatory requirements; a lack of acceptance of Vanda's product candidates in the marketplace, or a failure to become or remain profitable; Vanda's inability to obtain the capital necessary to fund its research and development activities; Vanda's failure to identify or obtain rights to new product candidates; Vanda's failure to develop or obtain sales, marketing and distribution resources and expertise or to otherwise manage its growth; a loss of any of Vanda's key scientists or management personnel; losses incurred from product liability claims made against Vanda; a loss of rights to develop and commercialize Vanda's products under its license and sublicense agreements and other factors that are described in the "Risk Factors" section (Part II, Item 1A) of Vanda's quarterly report on Form 10-Q for the quarter ended June 30, 2008 (File No. 000-51863). In addition to the risks described above and in Part II, Item 1A of Vanda's quarterly report on Form 10-Q, other unknown or unpredictable factors also could affect Vanda's results. There can be no assurance that the actual results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.

All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information in this release is provided only as of the date of this release, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Vanda Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
2. Vanda Presents Phase III Iloperidone Efficacy Data
3. Vanda Pharmaceuticals Receives FDA Acceptance of Iloperidone New Drug Application
4. Vanda Pharmaceuticals Reports Third Quarter 2007 Results
5. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
6. Cerimon Pharmaceuticals Announces Positive Results from a Phase II Clinical Study of Its Diclofenac Sodium Patch for Acute Pain
7. Jazz Pharmaceuticals, Inc. Announces Final Patient Has Completed Phase III Clinical Trial of Sodium Oxybate to Treat Fibromyalgia
8. Addrenex Pharmaceuticals Announces Positive Phase III Clinical Results for Clonicel to Treat ADHD
9. Celator Pharmaceuticals Receives Orphan Drug Designation for Anticancer Agent CPX-351
10. Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
11. Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Feb. 23, 2017 Nevro Corp. (NYSE: NVRO), a ... for the treatment of chronic pain, today reported financial results ... 2016. 2016 Accomplishment & Highlights: ... 2016, an increase of 228% as reported, over the prior ... an increase of 612% over the prior year ...
(Date:2/23/2017)... 2017 Research and Markets has announced the ... 2016" report to their offering. ... The latest research Fibromyalgia Drugs Price Analysis ... the global Fibromyalgia market. The research answers the following ... for Fibromyalgia and their clinical attributes? How are they positioned in ...
(Date:2/23/2017)... PUNE, India , February 23, 2017 ... "Diagnostic Imaging Market by Product (X-ray Imaging Digital, Analog), ... PET)), Application (OB/GYN, MSK, Cardiology, Oncology), End User (Hospitals, ... MarketsandMarkets, the report studies the global market over the ... expected to reach ~USD 36.43 Billion by 2021, at ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... February 24, 2017 , ... The California State ... convening academic faculty engaged in or interested in palliative care education and research. The ... be held in North County San Diego on Sept. 28 and 29, 2017, on ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... The International ... 7th annual “Imagine Me Beyond What You See” body image mannequin art competition. Selected ... will be showcased and the winner revealed at the 31st annual iaedp Symposium, March ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... The ... for excellence in radiology marketing programs at the annual Building Better Radiology Marketing ... Renaissance Fort Worth Hotel in Fort Worth, Texas. Nine awards are given out in ...
(Date:2/24/2017)... CA (PRWEB) , ... February 24, 2017 , ... ... for qualifying into the Senior International Elite division on February 12th. Ms. ... Around divisions at the elite qualifier competition held in Las Vegas, Nevada. Frida ...
(Date:2/23/2017)... ... 2017 , ... Thinksport, the most award-winning sunscreen on the ... Marin. For the second year in a row, cyclists will stay protected from ... thrilled to provide our safe, non-toxic sunscreen to over 2,000 cycling enthusiasts again ...
Breaking Medicine News(10 mins):